Clinical Trial

KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of KC1036 in combination with PD-1 antibody and platinum-based chemotherapy as a first-line treatment for patients with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-15.
Trial Details
NCT Number NCT07481058
Lead Sponsor Beijing Konruns Pharmaceutical Co., Ltd.
Conditions Esophageal Squamous Cell Carcinoma (ESCC)
Enrollment 60 participants
Start Date 2025-12-12
Primary Completion 2027-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-20